| Preoperative ipilimumab plus nivolumab in locoregionally advanced urothelial cancer: the NABUCCO trial N van Dijk, A Gil-Jimenez, K Silina, K Hendricksen, LA Smit, JM de Feijter, ... Nature medicine 26 (12), 1839-1844, 2020 | 308 | 2020 |
| Assessment of predictive genomic biomarkers for response to cisplatin-based neoadjuvant chemotherapy in bladder cancer A Gil-Jimenez, J van Dorp, A Contreras-Sanz, K van der Vos, DJ Vis, ... European urology 83 (4), 313-317, 2023 | 23 | 2023 |
| Atezolizumab with or without radiotherapy for advanced squamous cell carcinoma of the penis (the PERICLES study): a phase II trial HM de Vries, TS Rafael, A Gil-Jimenez, JM de Feijter, E Bekers, ... Journal of Clinical Oncology 41 (31), 4872-4880, 2023 | 21 | 2023 |
| The tumor immune landscape and architecture of tertiary lymphoid structures in urothelial cancer N Dijk, A Gil-Jimenez, K Silina, ML Montfoort, S Einerhand, L Jonkman, ... Frontiers in Immunology 12, 793964, 2021 | 17 | 2021 |
| Biomarker analysis and updated clinical follow-up of preoperative ipilimumab (ipi) plus nivolumab (nivo) in stage III urothelial cancer (NABUCCO). N Van Dijk, A Gil Jimenez, K Silina, K Hendricksen, L Smit, J De Feijter, ... Journal of Clinical Oncology 38 (15_suppl), 5020-5020, 2020 | 6 | 2020 |
| Gene-expression-based T-Cell-to-Stroma Enrichment (TSE) score predicts response to immune checkpoint inhibitors in urothelial cancer M Rijnders, JA Nakauma-González, DGJ Robbrecht, A Gil-Jimenez, ... Nature communications 15 (1), 1349, 2024 | 2 | 2024 |
| Spatial relationships in the urothelial and head and neck tumor microenvironment predict response to combination immune checkpoint inhibitors A Gil-Jimenez, N van Dijk, JL Vos, Y Lubeck, ML van Montfoort, D Peters, ... Nature communications 15 (1), 2538, 2024 | 1 | 2024 |
| T Cell-to-Stroma Enrichment (TSE) score: a gene expression metric that predicts response to immune checkpoint inhibitors in patients with urothelial cancer M Rijnders, JA Nakauma-González, DGJ Robbrecht, A Gil-Jimenez, ... bioRxiv, 2022.05. 30.493997, 2022 | 1 | 2022 |
| Platinum-based chemotherapy induces opposing effects on immunotherapy response-related spatial and stromal biomarkers in the bladder cancer microenvironment MA Chelushkin, J van Dorp, S van Wilpe, IM Seignette, JJJ Mellema, ... Clinical Cancer Research, 2024 | | 2024 |
| Clinical efficacy and biomarker analysis of pre-operative ipilimumab plus nivolumab in stage III urothelial cancer: The NABUCCO trial update. C Stockem, A Gil Jimenez, J van Dorp, N Van Dijk, ML van Montfoort, ... Journal of Clinical Oncology 42 (16_suppl), 4593-4593, 2024 | | 2024 |
| The penile cancer tumor microenvironment and immunotherapy response: Results from the PERICLES trial TS Rafael, A Gil-Jimenez, HM de Vries, IM Seignette, E Bekers, ... Cancer Research 84 (6_Supplement), 2488-2488, 2024 | | 2024 |
| Corrigendum to" Assessment of Predictive Genomic Biomarkers for Response to Cisplatin-based Neoadjuvant Chemotherapy in Bladder Cancer"[Eur Urol 2023; 83: 313-17] A Gil-Jimenez, J van Dorp, A Contreras-Sanz, K van der Vos, DJ Vis, ... European urology 83 (6), e165, 2023 | | 2023 |
| Spatial relationships in the tumor microenvironment predict response to immune checkpoint inhibitors in urothelial and head and neck cancer A Gil-Jimenez, N van Dijk, Y Lubeck, ML van Montfoort, D Peters, ... Cancer Research 83 (7_Supplement), 5786-5786, 2023 | | 2023 |
| Predicting pathological response after ipilimumab plus nivolumab in stage III urothelial cancer by liquid biopsy assessment of plasma and urine ctDNA using the RaDaR assay J van Dorp, C Pipinikas, N van Dijk, G Jones, A Gil-Jimenez, G Marsico, ... Cancer Research 82 (12), 2022 | | 2022 |
Daniel J. VisNetherlands Cancer Institute, Amsterdam, The Netherlands在 nki.nl 的电子邮件经过验证
